| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TRACLI.2009.04.004 |
| P698 | PubMed publication ID | 19427252 |
| P2093 | author name string | M A Blajchman | |
| P2860 | cites work | Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial | Q33360736 |
| The hazards of blood transfusion in historical perspective | Q34231829 | ||
| The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. | Q34560849 | ||
| Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. | Q34763224 | ||
| Improving the bacteriological safety of platelet transfusions | Q35613174 | ||
| Protecting the blood supply from emerging pathogens: the role of pathogen inactivation | Q36106339 | ||
| Modern plasma fractionation | Q36775707 | ||
| Pathogen inactivation: making decisions about new technologies. Report of a consensus conference | Q37013124 | ||
| Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies | Q37026225 | ||
| Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention | Q37384093 | ||
| Properties of pathogen-inactivated plasma components | Q37420043 | ||
| The continuing risk of transfusion-transmitted infections | Q45303244 | ||
| Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboons. | Q46292960 | ||
| Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop. | Q50610414 | ||
| Pathogen reduction: a precautionary principle paradigm. | Q50655717 | ||
| The impact of discontinuation of 7-day storage of apheresis platelets (PASSPORT) on recipient safety: an illustration of the need for proper risk assessments. | Q51127724 | ||
| Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004 | Q83314801 | ||
| Noninfectious serious hazards of transfusion | Q83367681 | ||
| P433 | issue | 2 | |
| P921 | main subject | emerging pathogen | Q108429945 |
| P304 | page(s) | 70-74 | |
| P577 | publication date | 2009-05-07 | |
| P1433 | published in | Transfusion Clinique et Biologique | Q15758506 |
| P1476 | title | Protecting the blood supply from emerging pathogens: the role of pathogen inactivation | |
| P478 | volume | 16 |
| Q38099101 | Analysis of reasons for not implementing pathogen inactivation for platelet concentrates. |
| Q40234714 | Blood system changes since recognition of transfusion-associated AIDS. |
| Q94682899 | Contemporary resuscitation of hemorrhagic shock: What will the future hold? |
| Q30369241 | Ebola virus convalescent blood products: where we are now and where we may need to go. |
| Q40330567 | Emergent viral threats in blood transfusion |
| Q28085648 | Is transfusion-transmitted dengue fever a potential public health threat? |
| Q24282614 | Solvent/Detergent Virally Inactivated Serum Eye Drops Restore Healthy Ocular Epithelium in a Rabbit Model of Dry-Eye Syndrome |
| Q37798900 | The status of pathogen-reduced plasma |
| Q37770409 | Transfusion medicine and proteomics. Alliance or coexistence? |
| Q38279968 | “Go no Go” in plasma fractionation in the world’s emerging economies: still a question asked 70 years after the COHN process was developed! |
Search more.